COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

S0820, Adenoma and Second Primary Prevention Trial

The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and second primary colorectal cancers in patients previously treated for Stages 0 through III colon or rectal cancer.

Research Base: Southwest Oncology Group
NCT ID: NCT01349881
NCI Protocol Number: SWOG-S0820
Status: Recruiting

For more information see ClinicalTrials.gov

Interventions

Condition

Colorectal Neoplasms

Trial Type

Cancer Prevention

See a list of participating sites on ClinicalTrials.gov


˄
BACK TO
TOP